Yong-Hee Kim
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Yong-Hee Kim has a total of 142 co-authors. Here are the top co-authors by number of shared publications:
- Jae Kwang Yun
Department of Thoracic and Cardiovascular Surgery, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Republic of Korea
23 shared publications Hyeong Ryul Kim
Department of Thoracic and Cardiovascular Surgery, Asan Medical Center, University of Ulsan College of Medicine, 88, Olympic-ro 43-gil, Songpa-gu, Seoul, 05505, Republic of Korea
21 shared publications- Seung-Il Park
Department of Thoracic and Cardiovascular Surgery, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Republic of Korea
21 shared publications - Dong Kwan Kim
Department of Thoracic and Cardiovascular Surgery, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Republic of Korea
19 shared publications - Sehoon Choi
Department of Thoracic and Cardiovascular Surgery, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Republic of Korea
19 shared publications - Hyeong Ryul Kim
Department of Thoracic and Cardiovascular Surgery, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Republic of Korea
18 shared publications
Latest Publications
- Open Access
- 11 August 2026
- Published by Wolters Kluwer Health in International Journal of Surgery
Reframing nodal staging in non–small-cell lung cancer: development and external validation of a metastatic node-count classification versus the 9th-edition N descriptor
Background: The 9th-edition TNM system for non–small-cell lung cancer subdivides N2 disease. The number-based nodal (nN) classification has shown prognostic performance similar to that of the 8th N descriptor, but comparisons with the 9th N descriptor are limited. We aimed to identify statistically valid cutoffs for the nN classification and compare its prognostic discrimination with that of the 9th N descriptor. Materials and methods: Patients with non–small-cell lung cancer who underwent lobectomy or a more extensive resection were included in the study. The SEER database (2010–2022) served as the training cohort, and an institutional dataset (2005–2022) served as the validation cohort. These two cohorts were not merged and were analyzed independently. Optimal cutoffs for the nN classification were identified using pairwise log-rank tests and multivariable Cox models in the validation cohort. Prognostic performance for overall survival was assessed in the validation cohort. Results: A total of 18 294 patients in the training cohort and 7386 patients in the validation cohort were analyzed. In the training cohort, cutoffs of 1 and 4 metastatic lymph nodes were identified, defining four nN classes (0, 1, 2–4, and ≥5). In the validation cohort, 5-year overall survival rates by nN class were 85.6%, 68.7%, 61.2%, and 44.4%, and all adjacent class comparisons were significant in multivariable Cox models ( P < 0.001). Prognostic discrimination was similar between the nN classification and the 9th N descriptor (5-year net reclassification improvement = 0.000; P = 0.893). The two systems showed moderate correlation (ρ = 0.601; P < 0.001). In the single-node metastasis subgroup, survival did not differ between N1 and N2a, whereas patients with ≥5 metastatic lymph nodes had worse survival in N2a and N2b ( P < 0.001 and P = 0.043). Conclusion: In patients undergoing upfront surgery, the nN classification provides prognostic discrimination equivalent to the 9th N descriptor and may serve as a complementary tool. Its generalizability after neoadjuvant therapy remains uncertain.
- 11 August 2026
- Published by Wolters Kluwer Health in International Journal of Surgery
Open AccessReframing nodal staging in non–small-cell lung cancer: development and external validation of a metastatic node-count classification versus the 9th-edition N descriptor
Background: The 9th-edition TNM system for non–small-cell lung cancer subdivides N2 disease. The number-based nodal (nN) classification has shown prognostic performance similar to that of the 8th N descriptor, but comparisons with the 9th N descriptor are limited. We aimed to identify statistically valid cutoffs for the nN classification and compare its prognostic discrimination with that of the 9th N descriptor. Materials and methods: Patients with non–small-cell lung cancer who underwent lobectomy or a more extensive resection were included in the study. The SEER database (2010–2022) served as the training cohort, and an institutional dataset (2005–2022) served as the validation cohort. These two cohorts were not merged and were analyzed independently. Optimal cutoffs for the nN classification were identified using pairwise log-rank tests and multivariable Cox models in the validation cohort. Prognostic performance for overall survival was assessed in the validation cohort. Results: A total of 18 294 patients in the training cohort and 7386 patients in the validation cohort were analyzed. In the training cohort, cutoffs of 1 and 4 metastatic lymph nodes were identified, defining four nN classes (0, 1, 2–4, and ≥5). In the validation cohort, 5-year overall survival rates by nN class were 85.6%, 68.7%, 61.2%, and 44.4%, and all adjacent class comparisons were significant in multivariable Cox models ( P < 0.001). Prognostic discrimination was similar between the nN classification and the 9th N descriptor (5-year net reclassification improvement = 0.000; P = 0.893). The two systems showed moderate correlation (ρ = 0.601; P < 0.001). In the single-node metastasis subgroup, survival did not differ between N1 and N2a, whereas patients with ≥5 metastatic lymph nodes had worse survival in N2a and N2b ( P < 0.001 and P = 0.043). Conclusion: In patients undergoing upfront surgery, the nN classification provides prognostic discrimination equivalent to the 9th N descriptor and may serve as a complementary tool. Its generalizability after neoadjuvant therapy remains uncertain.
- Open Access
- 9 July 2026
- Published by Elsevier in SSRN Electronic Journal
Lymphovascular invasion refines risk stratification beyond the 9th edition TNM classification in pathologic stage I non-small cell lung cancer
ObjectivesTo evaluate whether lymphovascular invasion (LVI) provides additional prognostic information beyond the 9th edition TNM classification in patients with pathologic stage I non-small cell lung cancer (NSCLC).Materials and methodsPatients with pathologic stage I NSCLC who underwent curative-intent resection between 2010 and 2020 were retrospectively reviewed. Overall survival (OS) and recurrence-free survival (RFS) were analyzed using the Kaplan–Meier method and Cox regression models. The incremental prognostic value of LVI was assessed by comparing model performance with and without LVI. Subgroup analyses were performed according to stage, histology, surgical extent, and visceral pleural invasion status.ResultsAmong 3,901 patients, 556 (14.3%) had LVI-positive tumors. During a median follow-up of 64 months, the LVI-positive group had significantly lower 5-year OS (81.9% vs. 92.0%; P < 0.001) and RFS (63.3% vs. 84.3%; P < 0.001) than the LVI-negative group. On multivariable analysis, LVI remained an independent predictor of OS (hazard ratio [HR], 1.47; 95% confidence interval [CI], 1.21–1.78; P < 0.001) and RFS (HR, 1.74; 95% CI, 1.49–2.04; P < 0.001). Incorporating LVI into tumor size and the 9th edition TNM classification demonstrated stepwise survival trends, and the addition of LVI improved model performance for both OS and RFS. The adverse prognostic impact of LVI was consistently observed across clinically relevant subgroups.ConclusionsLVI was independently associated with worse OS and RFS in pathologic stage I NSCLC. Incorporating LVI improved prognostic model performance and refined risk stratification within the 9th TNM stage groups, supporting its complementary role beyond conventional anatomic staging.
- 9 July 2026
- Published by Elsevier in SSRN Electronic Journal
Open AccessLymphovascular invasion refines risk stratification beyond the 9th edition TNM classification in pathologic stage I non-small cell lung cancer
ObjectivesTo evaluate whether lymphovascular invasion (LVI) provides additional prognostic information beyond the 9th edition TNM classification in patients with pathologic stage I non-small cell lung cancer (NSCLC).Materials and methodsPatients with pathologic stage I NSCLC who underwent curative-intent resection between 2010 and 2020 were retrospectively reviewed. Overall survival (OS) and recurrence-free survival (RFS) were analyzed using the Kaplan–Meier method and Cox regression models. The incremental prognostic value of LVI was assessed by comparing model performance with and without LVI. Subgroup analyses were performed according to stage, histology, surgical extent, and visceral pleural invasion status.ResultsAmong 3,901 patients, 556 (14.3%) had LVI-positive tumors. During a median follow-up of 64 months, the LVI-positive group had significantly lower 5-year OS (81.9% vs. 92.0%; P < 0.001) and RFS (63.3% vs. 84.3%; P < 0.001) than the LVI-negative group. On multivariable analysis, LVI remained an independent predictor of OS (hazard ratio [HR], 1.47; 95% confidence interval [CI], 1.21–1.78; P < 0.001) and RFS (HR, 1.74; 95% CI, 1.49–2.04; P < 0.001). Incorporating LVI into tumor size and the 9th edition TNM classification demonstrated stepwise survival trends, and the addition of LVI improved model performance for both OS and RFS. The adverse prognostic impact of LVI was consistently observed across clinically relevant subgroups.ConclusionsLVI was independently associated with worse OS and RFS in pathologic stage I NSCLC. Incorporating LVI improved prognostic model performance and refined risk stratification within the 9th TNM stage groups, supporting its complementary role beyond conventional anatomic staging.
- 30 May 2026
- Published by Elsevier in Lung Cancer
- Vol. 218, 109474
Refining N1 classification: prognostic validation of N1 subdivision in resected non-small cell lung cancer
- 30 May 2026
- Published by Elsevier in Lung Cancer
- Vol. 218, 109474
Refining N1 classification: prognostic validation of N1 subdivision in resected non-small cell lung cancer
- 28 January 2026
- Published by Oxford University Press (OUP) in European Journal of Cardio-Thoracic Surgery
- Vol. 68 (2)
Recurrence Patterns of Oesophageal Squamous Cell Carcinoma Differ by Tumour Location and Pathologic Stage
Objectives: To investigate how recurrence patterns in oesophageal squamous cell carcinoma (ESCC) are influenced by primary tumour location, treatment modality, and pathologic stage, and distinguish true recurrence from frequent secondary primary malignancies. Methods: A total of 953 ESCC patients (mean age, 62.6 ± 7.7 years, 883 [92.7%] male) who underwent curative-intent oesophagectomy between 2010 and 2020 were retrospectively analysed. Patients were categorized by tumour location (upper/mid vs lower), pathologic stage (0-I vs II-IV), and treatment modality (upfront surgery vs neoadjuvant chemoradiation). Recurrence patterns were classified as loco-regional, distant, or mixed. Secondary primary malignancies were also documented. Associations between recurrence patterns and post-recurrence survival (PRS) were assessed using multivariable Cox regression. Results: Recurrence occurred in 23.4% (223/953) of patients, mostly within 2 years post-surgery (83.4%). Among early pathologic stage (0-I) patients treated with upfront surgery, upper/mid oesophageal cancers had a higher rate of loco-regional recurrence compared with lower oesophageal cancers (16.3% vs 6.7%; P = .003), particularly in the mediastinal (10.9% vs 4.8%) and supraclavicular lymph nodes (6.3% vs 1.4%). No location-related differences were observed in advanced pathologic stage (II-IV) or neoadjuvant chemoradiation groups. Distant recurrence predominated in the neoadjuvant chemotherapy group (19.6% vs 9.7%). The lung was the most frequent site of distant metastasis (7.6%-8.6%), presenting as solitary nodules (24/45). Secondary lung cancers occurred later than pulmonary recurrences (median 58.3 vs 6.9 months; P < .001). Mixed recurrence was associated with worse PRS (adjusted hazard ratio, 1.77; 95% confidence interval, 1.18-2.66; P = .006). Conclusions: ESCC recurrence patterns vary by tumour location, treatment modality, and pathologic stage. The lung is the most common site of distant recurrence and presents earlier than secondary lung cancer.
- 28 January 2026
- Published by Oxford University Press (OUP) in European Journal of Cardio-Thoracic Surgery
- Vol. 68 (2)
Recurrence Patterns of Oesophageal Squamous Cell Carcinoma Differ by Tumour Location and Pathologic Stage
Objectives: To investigate how recurrence patterns in oesophageal squamous cell carcinoma (ESCC) are influenced by primary tumour location, treatment modality, and pathologic stage, and distinguish true recurrence from frequent secondary primary malignancies. Methods: A total of 953 ESCC patients (mean age, 62.6 ± 7.7 years, 883 [92.7%] male) who underwent curative-intent oesophagectomy between 2010 and 2020 were retrospectively analysed. Patients were categorized by tumour location (upper/mid vs lower), pathologic stage (0-I vs II-IV), and treatment modality (upfront surgery vs neoadjuvant chemoradiation). Recurrence patterns were classified as loco-regional, distant, or mixed. Secondary primary malignancies were also documented. Associations between recurrence patterns and post-recurrence survival (PRS) were assessed using multivariable Cox regression. Results: Recurrence occurred in 23.4% (223/953) of patients, mostly within 2 years post-surgery (83.4%). Among early pathologic stage (0-I) patients treated with upfront surgery, upper/mid oesophageal cancers had a higher rate of loco-regional recurrence compared with lower oesophageal cancers (16.3% vs 6.7%; P = .003), particularly in the mediastinal (10.9% vs 4.8%) and supraclavicular lymph nodes (6.3% vs 1.4%). No location-related differences were observed in advanced pathologic stage (II-IV) or neoadjuvant chemoradiation groups. Distant recurrence predominated in the neoadjuvant chemotherapy group (19.6% vs 9.7%). The lung was the most frequent site of distant metastasis (7.6%-8.6%), presenting as solitary nodules (24/45). Secondary lung cancers occurred later than pulmonary recurrences (median 58.3 vs 6.9 months; P < .001). Mixed recurrence was associated with worse PRS (adjusted hazard ratio, 1.77; 95% confidence interval, 1.18-2.66; P = .006). Conclusions: ESCC recurrence patterns vary by tumour location, treatment modality, and pathologic stage. The lung is the most common site of distant recurrence and presents earlier than secondary lung cancer.
- 28 October 2025
- Published by Oxford University Press (OUP) in European Journal of Cardio-Thoracic Surgery
- Vol. 67 (11)
Comparison of Short-Term Surgical Outcomes for Thymectomy With Various Minimally Invasive Approaches: A Single-Centre Experience
Objectives: Minimally invasive thymectomy, encompassing video-assisted thoracoscopic surgery and robotic-assisted thoracic surgery, is increasingly being adopted as an alternative to sternotomy. However, comparative data on commonly used minimally invasive techniques remain limited. This study aimed to compare the short-term surgical outcomes of 3 approaches: lateral video-assisted thoracoscopic surgery, lateral robotic-assisted thoracic surgery and subxiphoid robotic-assisted thoracic surgery. Methods: We retrospectively reviewed 292 patients who underwent minimally invasive thymectomy for anterior mediastinal masses between October 2020 and April 2024. Patients were categorized into 3 groups according to the surgical approach. Perioperative outcomes, including operating time, postoperative pain, hospital stay, and complications, were compared. Results: Of the 292 patients, 155 underwent lateral video-assisted thoracoscopic surgery; 70 underwent lateral robotic-assisted thoracic surgery; and 67 underwent subxiphoid robotic-assisted thoracic surgery. Operative time was significantly longer in both robotic-assisted thoracic surgery groups compared to video-assisted thoracoscopic surgery (lateral robotic-assisted thoracic surgery: 118.7 min; subxiphoid robotic-assisted thoracic surgery: 116.7 min; video-assisted thoracoscopic surgery: 93.5 min; P < .001). No significant differences were observed among the 3 groups in terms of postoperative pain, chest tube duration, hospital stay, complication rate, or R0 resection. No in-hospital deaths occurred. Conclusions: All 3 minimally invasive approaches for thymectomy demonstrated comparable short-term outcomes, although robotic-assisted thoracic surgery procedures had longer operating times. These findings suggest that lateral video-assisted thoracoscopic surgery, lateral robotic-assisted thoracic surgery, and subxiphoid robotic-assisted thoracic surgery are all safe and effective options, enabling surgeons to select the most appropriate technique based on individual patient characteristics and their surgical expertise.
- 28 October 2025
- Published by Oxford University Press (OUP) in European Journal of Cardio-Thoracic Surgery
- Vol. 67 (11)
Comparison of Short-Term Surgical Outcomes for Thymectomy With Various Minimally Invasive Approaches: A Single-Centre Experience
Objectives: Minimally invasive thymectomy, encompassing video-assisted thoracoscopic surgery and robotic-assisted thoracic surgery, is increasingly being adopted as an alternative to sternotomy. However, comparative data on commonly used minimally invasive techniques remain limited. This study aimed to compare the short-term surgical outcomes of 3 approaches: lateral video-assisted thoracoscopic surgery, lateral robotic-assisted thoracic surgery and subxiphoid robotic-assisted thoracic surgery. Methods: We retrospectively reviewed 292 patients who underwent minimally invasive thymectomy for anterior mediastinal masses between October 2020 and April 2024. Patients were categorized into 3 groups according to the surgical approach. Perioperative outcomes, including operating time, postoperative pain, hospital stay, and complications, were compared. Results: Of the 292 patients, 155 underwent lateral video-assisted thoracoscopic surgery; 70 underwent lateral robotic-assisted thoracic surgery; and 67 underwent subxiphoid robotic-assisted thoracic surgery. Operative time was significantly longer in both robotic-assisted thoracic surgery groups compared to video-assisted thoracoscopic surgery (lateral robotic-assisted thoracic surgery: 118.7 min; subxiphoid robotic-assisted thoracic surgery: 116.7 min; video-assisted thoracoscopic surgery: 93.5 min; P < .001). No significant differences were observed among the 3 groups in terms of postoperative pain, chest tube duration, hospital stay, complication rate, or R0 resection. No in-hospital deaths occurred. Conclusions: All 3 minimally invasive approaches for thymectomy demonstrated comparable short-term outcomes, although robotic-assisted thoracic surgery procedures had longer operating times. These findings suggest that lateral video-assisted thoracoscopic surgery, lateral robotic-assisted thoracic surgery, and subxiphoid robotic-assisted thoracic surgery are all safe and effective options, enabling surgeons to select the most appropriate technique based on individual patient characteristics and their surgical expertise.
- 25 October 2025
- Published by Oxford University Press (OUP) in European Journal of Cardio-Thoracic Surgery
- Vol. 67 (11)
Quantitative Analysis of Changes in the Thoracic Anatomy over Time after Pneumonectomy Using Computed Tomography
Objectives: The rate and extent of hemithorax volume reduction on the operated side, corresponding compensatory volume increase on the contralateral side, and mediastinal angle shift following pneumonectomy have not been quantitatively analysed. This study aimed to quantify these time-dependent changes in thoracic anatomy after pneumonectomy. Methods: Patients who underwent pneumonectomy between April 2003 and June 2019 were retrospectively included. The volume of each hemithorax and the mediastinal shift angle were quantified using computed tomography scans taken pre- and postoperatively (6 months, 1, 2, and 3 years after surgery). Results: Finally, 119 patients (median age, 58.5 years; 95 men) were evaluated. The pneumonectomy site volume decreased to 25% and 37% of the original volume in the left and right pneumonectomy, respectively, over 3 years, with 21%-24% hyperinflation in the non-operated hemithorax. Mediastinal shifting towards the pneumonectomy side was observed as an increased angle (from 7.1° to 21.4° for the left pneumonectomy and from 4.4° to 20.3° for the right pneumonectomy). Volume reduction was significant until the first 6 months for right pneumonectomy and 1 year for left pneumonectomy (all P < .05), while hyperinflation and mediastinal shifting stabilized after 6 months. Left pneumonectomy showed a more abrupt volume decrease than right pneumonectomy during the observed period (all P < .05). Conclusions: Significant anatomical changes occur within the first 6 months after a pneumonectomy. Thereafter, the magnitude of change decreases, and the thoracic structures reach a steady state by 2 to 3 years postoperatively. Clinical Registration Number: None.
- 25 October 2025
- Published by Oxford University Press (OUP) in European Journal of Cardio-Thoracic Surgery
- Vol. 67 (11)
Quantitative Analysis of Changes in the Thoracic Anatomy over Time after Pneumonectomy Using Computed Tomography
Objectives: The rate and extent of hemithorax volume reduction on the operated side, corresponding compensatory volume increase on the contralateral side, and mediastinal angle shift following pneumonectomy have not been quantitatively analysed. This study aimed to quantify these time-dependent changes in thoracic anatomy after pneumonectomy. Methods: Patients who underwent pneumonectomy between April 2003 and June 2019 were retrospectively included. The volume of each hemithorax and the mediastinal shift angle were quantified using computed tomography scans taken pre- and postoperatively (6 months, 1, 2, and 3 years after surgery). Results: Finally, 119 patients (median age, 58.5 years; 95 men) were evaluated. The pneumonectomy site volume decreased to 25% and 37% of the original volume in the left and right pneumonectomy, respectively, over 3 years, with 21%-24% hyperinflation in the non-operated hemithorax. Mediastinal shifting towards the pneumonectomy side was observed as an increased angle (from 7.1° to 21.4° for the left pneumonectomy and from 4.4° to 20.3° for the right pneumonectomy). Volume reduction was significant until the first 6 months for right pneumonectomy and 1 year for left pneumonectomy (all P < .05), while hyperinflation and mediastinal shifting stabilized after 6 months. Left pneumonectomy showed a more abrupt volume decrease than right pneumonectomy during the observed period (all P < .05). Conclusions: Significant anatomical changes occur within the first 6 months after a pneumonectomy. Thereafter, the magnitude of change decreases, and the thoracic structures reach a steady state by 2 to 3 years postoperatively. Clinical Registration Number: None.
- 1 October 2025
- Published by Radiological Society of North America (RSNA) in Radiology
- Vol. 317 (1) , e250415
Recurrence Risk Following Percutaneous Transthoracic Needle Biopsy in Patients Undergoing Sublobar Resection for Stage I Lung Cancer
In patients undergoing sublobar resection for pathologic stage I lung cancer, preoperative percutaneous transthoracic biopsy was associated with an increased risk of local-regional recurrence, especially in the remnant lung.
- 1 October 2025
- Published by Radiological Society of North America (RSNA) in Radiology
- Vol. 317 (1) , e250415
Recurrence Risk Following Percutaneous Transthoracic Needle Biopsy in Patients Undergoing Sublobar Resection for Stage I Lung Cancer
In patients undergoing sublobar resection for pathologic stage I lung cancer, preoperative percutaneous transthoracic biopsy was associated with an increased risk of local-regional recurrence, especially in the remnant lung.
- 28 August 2025
- Published by Oxford University Press (OUP) in European Journal of Cardio-Thoracic Surgery
- Vol. 67 (9)
Beyond the Lung: Distinct Recurrence Patterns of Mucinous and Non-mucinous Lung Adenocarcinoma After Surgery
Objectives: This study aimed to investigate differences in recurrence patterns between invasive mucinous adenocarcinoma and non-mucinous adenocarcinoma following surgical resection in patients with lung cancer without nodal or systemic metastasis. Methods: We retrospectively analysed the patients’ data who underwent curative surgery for adenocarcinoma between 2011 and 2021. To balance clinical characteristics, 2:1 propensity score matching was performed. Recurrence patterns were classified as either intrapulmonary or extrapulmonary recurrence. Freedom from recurrence and cumulative incidence of recurrence were analysed to assess differences between groups. Results: A total of 4919 patients were included. After matching, 722 patients were non-mucinous group, and 368 patients were mucinous group. The mucinous group exhibited significantly higher freedom from recurrence (P = .033) compared to the non-mucinous group. The overall recurrence rate was lower in the mucinous group (8.4% vs 13.0%, P = .035). Although the incidence of intrapulmonary recurrence was comparable between groups (P = .50), extrapulmonary recurrence was significantly lower in the mucinous group (P = .02). Fine and Gray’s multivariable analysis identified invasive mucinous histology as an independent factor associated with a lower risk of extrapulmonary recurrence (HR = 0.45; 95% CI, 0.22-0.89, P = .023). Visceral pleural invasion was a significant predictor for extrapulmonary recurrence (HR = 2.89; 95% CI, 1.37-6.09; P = .005). Conclusions: The invasive mucinous adenocarcinoma group demonstrate better recurrence-free survival and a lower risk of extrapulmonary recurrence compared to the non-mucinous group following surgical resection. These findings highlight the need for further research aimed at developing tailored surveillance and treatment strategies based on tumour histological characteristics.
- 28 August 2025
- Published by Oxford University Press (OUP) in European Journal of Cardio-Thoracic Surgery
- Vol. 67 (9)
Beyond the Lung: Distinct Recurrence Patterns of Mucinous and Non-mucinous Lung Adenocarcinoma After Surgery
Objectives: This study aimed to investigate differences in recurrence patterns between invasive mucinous adenocarcinoma and non-mucinous adenocarcinoma following surgical resection in patients with lung cancer without nodal or systemic metastasis. Methods: We retrospectively analysed the patients’ data who underwent curative surgery for adenocarcinoma between 2011 and 2021. To balance clinical characteristics, 2:1 propensity score matching was performed. Recurrence patterns were classified as either intrapulmonary or extrapulmonary recurrence. Freedom from recurrence and cumulative incidence of recurrence were analysed to assess differences between groups. Results: A total of 4919 patients were included. After matching, 722 patients were non-mucinous group, and 368 patients were mucinous group. The mucinous group exhibited significantly higher freedom from recurrence (P = .033) compared to the non-mucinous group. The overall recurrence rate was lower in the mucinous group (8.4% vs 13.0%, P = .035). Although the incidence of intrapulmonary recurrence was comparable between groups (P = .50), extrapulmonary recurrence was significantly lower in the mucinous group (P = .02). Fine and Gray’s multivariable analysis identified invasive mucinous histology as an independent factor associated with a lower risk of extrapulmonary recurrence (HR = 0.45; 95% CI, 0.22-0.89, P = .023). Visceral pleural invasion was a significant predictor for extrapulmonary recurrence (HR = 2.89; 95% CI, 1.37-6.09; P = .005). Conclusions: The invasive mucinous adenocarcinoma group demonstrate better recurrence-free survival and a lower risk of extrapulmonary recurrence compared to the non-mucinous group following surgical resection. These findings highlight the need for further research aimed at developing tailored surveillance and treatment strategies based on tumour histological characteristics.
- Open Access
- 1 July 2025
- Published by AME Publishing Company in Journal of Thoracic Disease
- Vol. 17 (7) , 4610-4620
Is a paradigm shift from conventional to robotic approaches necessary in first rib resection for thoracic outlet syndrome?
Background: Thoracic outlet syndrome (TOS) is a group of disorders caused by compression of the neurovascular bundle as it exits the thoracic outlet. The treatment involves first rib resection (FRR) via open surgery or minimally invasive surgery. This study compares the surgical outcomes of the supraclavicular approach and robotic-assisted thoracic surgery (RATS). Methods: We retrospectively reviewed the clinicopathological and perioperative data of patients with TOS who underwent surgery between October 2005 and July 2024. Results: A total of 23 operations were performed on 21 patients (median age, 28 years; range, 21–68 years), with 8 (38.1%) being female. The median body mass index (BMI) was 23.7 kg/m2 (range, 20.5–42.5 kg/m2), and 15 patients had neurogenic TOS (nTOS). Among the 23 cases, robotic FRR was performed in 13 cases. The median operation time was 96 min (range, 63–211 min), and the median highest pain score on the numeric rating scale (NRS) was 3 (range, 1–7). One patient (4.3%) experienced subclavian artery injury which was successfully repaired without sequelae. Based on the Derkash classification, clinical outcomes were categorized as “excellent”, which was the most prevalent category, in 19 patients (82.6%). The median subjective improvement was 95% (range, 60–100%). Postoperative peak NRS scores were better with robotic FRR compared to the supraclavicular approach (3 vs. 4.5; P=0.02). Conclusions: In appropriately selected patients, both supraclavicular and robotic FRR yield excellent surgical outcomes. However, given its various advantages, robotic FRR should be considered the new gold standard when a robotic system is available at the institution.
- 1 July 2025
- Published by AME Publishing Company in Journal of Thoracic Disease
- Vol. 17 (7) , 4610-4620
Open AccessIs a paradigm shift from conventional to robotic approaches necessary in first rib resection for thoracic outlet syndrome?
Background: Thoracic outlet syndrome (TOS) is a group of disorders caused by compression of the neurovascular bundle as it exits the thoracic outlet. The treatment involves first rib resection (FRR) via open surgery or minimally invasive surgery. This study compares the surgical outcomes of the supraclavicular approach and robotic-assisted thoracic surgery (RATS). Methods: We retrospectively reviewed the clinicopathological and perioperative data of patients with TOS who underwent surgery between October 2005 and July 2024. Results: A total of 23 operations were performed on 21 patients (median age, 28 years; range, 21–68 years), with 8 (38.1%) being female. The median body mass index (BMI) was 23.7 kg/m2 (range, 20.5–42.5 kg/m2), and 15 patients had neurogenic TOS (nTOS). Among the 23 cases, robotic FRR was performed in 13 cases. The median operation time was 96 min (range, 63–211 min), and the median highest pain score on the numeric rating scale (NRS) was 3 (range, 1–7). One patient (4.3%) experienced subclavian artery injury which was successfully repaired without sequelae. Based on the Derkash classification, clinical outcomes were categorized as “excellent”, which was the most prevalent category, in 19 patients (82.6%). The median subjective improvement was 95% (range, 60–100%). Postoperative peak NRS scores were better with robotic FRR compared to the supraclavicular approach (3 vs. 4.5; P=0.02). Conclusions: In appropriately selected patients, both supraclavicular and robotic FRR yield excellent surgical outcomes. However, given its various advantages, robotic FRR should be considered the new gold standard when a robotic system is available at the institution.